Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm
Executive Summary
Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med entrectinib – good but perhaps not as good as others.
You may also be interested in...
Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi
Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.
Pediatric Oncology Advances Could Prompt More FDA-Required Studies
Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.
Pediatric Oncology Advances Could Prompt More FDA-Required Studies
Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.